Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment

Pharmacology and Therapeutics

Volumn 111, Issue 1, 2006, Pages 224-259

  Judge, Susan I V ^a,b   Bever Jr , Christopher T ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

3,4 diaminopyridine; 4 aminopyridine; Channel blockers; Clinical trials; Multiple sclerosis; Potassium channel nomenclature; Venom derived peptide toxins; Voltage gated potassium channels

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; AMIODARONE; ANANDAMIDE; ARACHIDONIC ACID; ASTEMIZOLE; AZIMILIDE; BARIUM; BEPRIDIL; CADMIUM; CALCIUM; CESIUM; CISAPRIDE; COBALT; COCAINE; GADOLINIUM; HYDROGEN; LANTHANUM; LEAD; LITHIUM; MAGNESIUM; MANGANESE; MERCURY; NICKEL; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM; STRONTIUM; UNINDEXED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; ZINC;

ABDOMINAL PAIN; ANXIETY; ASTHENIA; BINDING SITE; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DEMYELINATION; DIZZINESS; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HEADACHE; HUMAN; INSOMNIA; MORPHOLOGY; MULTIPLE SCLEROSIS; NAUSEA; NERVE CONDUCTION; NERVE FIBER; NEUROPHYSIOLOGY; PAIN; PALLIATIVE THERAPY; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SLOW DRUG RELEASE; TREMOR;

4-AMINOPYRIDINE; ANIMALS; HUMANS; MULTIPLE SCLEROSIS; NEURONS; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED;

EID: 33646776060     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.10.006     Document Type: Review

References (431)

1. Adam K.R., Schmidt H., Stämpfli R., and Weiss C. The effect of scorpion venom on single myelinated fibres of frog. Br J Pharmacol 26 (1966) 666-677
2. Aguera y Arcas B., Fairhall A.L., and Bialek W. Computation in a single neuron: Hodgkin and Huxley revisited. Neural Comput 15 (2003) 1715-1749
3. Ahern C.A., and Horn R. Stirring up controversy with a voltage sensor paddle. Trends Neurosci 27 (2004) 303-307
4. Akhtar S., Shamotienko O., Papakosta M., Ali F., and Dolly O. Characteristics of brain Kv1 channels tailored to mimic native counterparts by tandem linkage of α subunits. J Biol Chem 277 (2002) 16376-16382
5. Alessandri-Haber N., Lecoq A., Gasparini S., Grangier-Macmath G., Jacquet G., Harvey A.L., et al. Mapping the functional anatomy of BgK on Kv1.1, Kv1.2, and Kv1.3. J Biochem 274 (1999) 35653-35661
6. + Channel Blocker, Data Sheet at http://www.alomone.com.
7. Armstrong C.M. Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons. J Gen Physiol 58 (1971) 413-437
8. Armstrong C.M., and Bezanilla F. Charge movement associated with the opening and closing of the activation gates of the Na channels. J Gen Physiol 63 (1974) 533-552
9. Armstrong C.M., and Loboda A. A model for 4-aminopyridine action on K channels: similarities to tetraethylammonium ion action. Biophys J 81 (2001) 895-904
10. Arroyo E.J., and Scherer S.S. On the molecular architecture of myelinated fibers. Histochem Cell Biol 113 (2000) 1-18
11. Arroyo E.J., Xu Y.T., Zhou L., Messing A., Peles E., Chiu S.Y., et al. Myelinating Schwann cells determine the internodal localization of Kv1.1, Kv1.2, Kvbeta2, and Caspr. J Neurocytol 28 (1999) 333-347
12. Arroyo E.J., Xu T., Poliak S., Watson M., Peles E., and Scherer S.S. Internodal specializations of myelinated axons in the central nervous system. Cell Tissue Res 305 (2001) 53-66
13. Arroyo E.J., Xu T., Grinspan J., Lambert S., Levinson S.R., Brophy P.J., et al. Genetic dysmyelination alters the molecular architecture of the nodal region. J Neurosci 22 (2002) 1726-1737
14. Arroyo E.J., Sirkowski E.E., Chitale R., and Scherer S.S. Acute demyelination disrupts the molecular organization of peripheral nervous system nodes. J Comp Neurol 479 (2004) 424-434
15. Ashcroft F.M. Ion Channels and Disease (2000), Academic Press, San Diego
16. + channel clustering. J Neurosci Res 58 (1999) 752-764
17. Bagdany M., Batista C.V., Valdez-Cruz N.A., Somodi S., Rodriguez de al Vega R.C., Licea A.F., et al. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes. Mol Pharmacol 67 (2005) 1034-1044
18. Bagust J., Zhang L., and Owen D. Toxin, I., but not 4-aminopyridine, blocks the late inhibitory component of the dorsal root reflex in an isolated preparation of rat spinal cord. Brain Res 773 (1997) 181-189
19. Bardien-Kruger S., Wulff H., Arieff Z., Brink P., Chandy K.G., and Corfield V. Characteristics of the human voltage-gated potassium channel gene, KCNA7, a candidate for inherited cardiac disorders and its exclusion as cause of progressive familial heart block I (PFHBI). Eur J Hum Genet 10 (2002) 36-43
20. Bayrhuber M., Vijayan V., Ferber M., Graf R., Korukottu J., Imperial J., et al. Conkunitzin-S1 is the first member of a new Kunitz-type neurotoxin family. J Biol Chem 280 (2005) 23766-23770
21. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol 166 (2001) 936-944
22. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A 98 (2001) 13942-13947
23. Beeton C., Pennington M.W., Wulff H., Singh S., Nugent D., Crossley G., et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune disease. Mol Pharmacol 67 (2005) 1369-1381
24. 2+- and voltage-activated potassium channels. J Biol Chem 276 (2001) 42116-42121
25. Bever C.T. 4-Aminopyridine: use in multiple sclerosis. CNS Drug Rev 1 (1994) 261-279
26. Bever C.T., Leslie J., Camenga D., Panitch H.S., and Johnson K.P. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann Neurol 27 (1990) 421-427
27. Bever C.T., Young D., Anderson P.M., Krumholz A., Conway K., Leslie J., et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized placebo-controlled, double-blind, concentration-controlled crossover trial. Neurology 44 (1994) 1054-1059
28. Bever C.T., Katz E., Tierney D., and Johnson K.P. Experience with slow release 4-aminopyridine in multiple sclerosis patients: long term tolerability and safety. J Neuroimmunol Suppl 1 (1995) 58
29. Bever Jr. C.T., Anderson P.A., Leslie J., Panitch H.S., Dhib-Jalbut S., Khan O.A., et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47 (1996) 1457-1462
30. Bezanilla F. Gating of sodium and potassium channels. J Membr Biol 88 (1985) 11-97
31. Bezanilla F., Perozo F., Papazian D.M., and Stefani E. Molecular basis of gating charge immobilization in Shaker potassium channels. Science 254 (1991) 679-683
32. Black A.R., Breeze A.L., Othman I.B., and Dolly J.O. Involvement of neuronal acceptors for dendrotoxin in its convulsive action in rat brain. Biochemistry 237 (1986) 397-404
33. + channel cloned from the rat cardiovascular system. FEBS Lett 295 (1991) 211-213
34. Bostock H., and Sears T.A. The internodal axon membrane: electrical excitability and continuous conduction in segmental demyelination. J Physiol 280 (1978) 273-301
35. Bostock H., Sherratt R.M., and Sears T.A. Overcoming conduction failure in demyelinated nerve fibres by prolonging the action potential. Nature 274 (1978) 385-387
36. Bostock H., Sears T.A., and Sherratt R.M. The effect of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated nerve fibres. J Physiol (Lond) 313 (1981) 301-315
37. Bouchard R., and Fedida D. Closed- and open-state binding of 4-aminopyridine to the cloned human potassium channel Kv1.5. J Pharmacol Exp Ther 274 (1995) 864-876
38. + channel in Xenopus nerve fibres selectively blocked by bee and snake toxins: binding and voltage-clamp experiments. J Physiol 420 (1990) 365-385
39. Braun P.E. Molecular organization of myelin. In: Morell P. (Ed). Myelin. 2nd ed. (1984), Plenum Press, New York 97-116
40. Breland A.E., and Currier R.D. Scorpion venom and multiple sclerosis. Lancet (1983) 1021
41. Brooke R.E., Atkinson L., Batten T.F.C., Deuchars S.A., and Deuchars J. Association of potassium channel Kv3.4 subunits with pre- and post-synaptic structures in brainstem and spinal cord. Neuroscience 126 (2004) 1001-1010
42. Butler A., Wei A., Baker K., and Salkoff L. A family of putative potassium channel genes in Drosophila. Science 243 (1989) 943-947
43. Butler A., Wei A.G., and Salkoff L. Shal, Shab, and Shaw: three genes encoding potassium channels in Drosophila. Nucleic Acids Res 18 (1990) 2173-2174
44. Cahalan M.D. Local anesthetic block of sodium channels in normal and pronase-treated squid giant axons. Biophys J 21 (1978) 285-311
45. Castle N.A., Fadous S., Logothetis D.E., and Wang G.K. Aminopyridine block of Kv1.1 potassium channels expressed in mammalian cells and Xenopus oocytes. Mol Pharmacol 45 (1994) 1242-1252
46. Castle N.A., Fadous S., Logothetis D.E., and Wang G.K. 4-Aminopyridine binding and slow inactivation are mutually exclusive in rat Kv1.1 and Shaker potassium channels. Mol Pharmacol 46 (1994) 1175-1181
47. Catterall W.A. Structure and function of voltage-sensitive ion channels. Science 242 (1988) 50-61
48. In: Catterall W.A., Chandy K.G., and Gutman G.A. (Eds). The IUPHAR Compendium of Voltage-Gated Ion Channels (2003), IUPHAR Media, Leeds
49. Chagot B., Escoubas P., Villegas E., Bernard C., Ferrat G., Corzo G., et al. Solution structure of Phrixotoxin 1, a specific inhibitor of Kv4 potassium channels from the venom of the theraphosid spider Phrixotrichus auratus. Protein Sci 13 (2004) 1197-1208
50. Chandy K.G. Simplified gene nomenclature. Nature 352 (1991) 26
51. Chandy K.G., and Gutman G.A. Voltage-gated potassium channel genes. In: North R.A. (Ed). Handbook of Receptors and Channels Ligand- and Voltage-Gated Ion Channels (1995), CRC Press, Boca Raton 1-71
52. Chandy K.G., Williams C.B., Spencer R.H., Aguilar B.A., Ghanshani S., Tempel B.L., et al. A family of three mouse potassium channel genes with intronless coding regions. Science 247 (1990) 973-975
53. + channels as targets for specific immunomodulation. Trends Pharmacol Sci 25 (2004) 280-289
54. Charcot, J. M. (1881). Lectures on the pathological anatomy of the nervous system, diseases of the spinal cord (Dr. Cornelius G Comegys, Trans., from reports by Dr. E Brissaud in the Progrés Medicale). Cincinnati: Peter G Thomson.
55. Chiu S.Y. The roles of potassium and calcium channels in physiology and pathophysiology of axons. In: Waxman S. (Ed). Multiple Sclerosis as a Neuronal Disease (2005), Elsevier Academic Press, Amsterdam 69-83
56. Chiu S.Y., and Ritchie J.M. Potassium channels in nodal and internodal axonal membrane of mammalian myelinated fibres. Nature 284 (1980) 170-171
57. + channels. Proc Natl Acad Sci U S A 88 (1991) 5092-5095
58. Choquet D., and Korn H. Mechanism of 4-aminopyridine action on voltage-gated potassium channels in lymphocytes. J Gen Physiol 99 (1992) 217-240
59. Christie M.J., Adelman J.P., Douglass J., and North R.A. Expression of a cloned rat brain potassium channel in Xenopus oocytes. Science 244 (1989) 221-224
60. Clay J.R. Axonal excitability revisited. Prog Biophys Mol Biol 88 (2005) 59-90
61. + channels. Ann N Y Acad Sci 868 (1999) 233-285
62. Cole K.S. Dynamic electrical characteristics of the squid axon membrane. Arch Sci Physiol 3 (1949) 253-258
63. Cole K.S. Membrane watching. J Gen Physiol 51 (1968) 1-7
64. Cole K.S. Membranes, Ions and Impulses: A Chapter of Classical Biophysics (1968), University of California Press, Berkeley
65. Cole K.S., and Curtis H.J. Electrical impedance of the squid giant axon during activity. J Gen Physiol 22 (1939) 649-670
66. Coleman S.K., Newcombe J., Pryke J., and Dolly O. Subunit composition of Kv1 channels in human CNS. J Neurochem 73 (1999) 849-858
67. Collier B., Padjen A.L., Quik M., and Smith P.A. Convulsant and possible anticholinergic actions of dendrotoxin in the amphibian spinal cord. Br J Pharmacol 73 (1981) 525-533
68. Connor J.A., and Stevens C.F. Prediction of repetitive firing behavior from voltage clamp data on an isolated neurone soma. J Physiol (Lond) 213 (1971) 31-53
69. Cotton J., Crest M., Bouet F., Alessandri N., Gola M., Forest E., et al. A potassium-channel toxin from the sea anemone Buodosoma granulifera, an inhibitor for Kv1 channels. Revision of the amino acid sequence, disulfide-bridge assignment. Eur J Biochem 244 (1997) 192-202
70. + current systems. Neuron 7 (1991) 763-773
71. Darbon H., and Sabatier J.M. Perspectives in Drug Discovery and Design: Animal Toxins and Potassium Channels (1999), Klewer/Escom, Dordrecht
72. Dauplais M., Lecoq A., Song J., Cotton J., Jamin N., Gilquin B., et al. On the convergent evolution of animal toxins. Conservation of a diad of functional residues in potassium channel-blocking toxins with unrelated structures. J Biol Chem 272 (1997) 4302-4309
73. Davis F.A., Stefoski D., and Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 27 (1990) 186-192
74. Debanne D. Information processing in the axon. Nat Rev 5 (2004) 304-316
75. + conductance in hippocampus. Nature 389 (1997) 286-289
76. Devaux J., Alcaraz G., Grinspan J., Bennett V., Joho R., Crest M., et al. Kv3.1b is a novel component of CNS nodes. J Neurosci 23 (2003) 4509-4518
77. Devaux J., Beeton C., Beraud E., and Crest M. Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers. (in French). Rev Neurol (Paris) 160 (2004) S16-S27
78. Diochot S., Schweitz H., Beress L., and Lazdunski M. Sea anemone peptides with a specific blocking activity against the fast inactivating potassium channel Kv3.4. J Biol Chem 273 (1998) 6744-6749
79. Diochot S., Loret E., Bruhn T., Béress L., and Lazdunski M. APETx1, a new toxin from the sea anemone Anthopleura elegantissima, blocks voltage-gated human Ether-a-go-go-related gene potassium channels. Mol Pharmacol 64 (2003) 59-69
80. Dodge F.A., and Frankenhaeuser B. Membrane currents in isolated frog nerve under voltage-clamp conditions. J Physiol (Lond) 143 (1958) 76-90
81. Dodge F.A., and Frankenhaeuser B. Sodium currents in the myelinated nerve fibre of Xenopus laevis investigated with the voltage clamp technique. J Physiol (Lond) 148 (1959) 188-200
82. + channels: electrifying regulators of synaptic terminal excitability. Trends Neurosci 27 (2004) 210-217
83. A currents) of cerebellum granular cells. Arch Biochem Biophys 430 (2004) 256-263
84. Dudina, E. E., Korolkova, Y. V., Bocharova, N. E., Koshelev, S. G., Egorov, T. A., Huys, I., et al. (2001). OsK2, A New Selective Inhibitor of Kv1.2 Potassium Channels Purified from the Venom of the Scorpion Orthochirus scrobiculosus.
85. + channel. Biophys J 87 (2004) 2116-2130
86. Ebbinghaus J., Legros C., Nolting A., Guette C., Celerier M.-L., Pongs O., et al. Modulation of Kv4.2 channels by a peptide isolated from the venom of the giant bird-eating tarantula Theraphosa leblondi. Toxicon 43 (2004) 923-932
87. Eder C. Ion channels in microglia (brain macrophages). Am J Physiol 275 (1998) C327-C342
88. Eder C. Ion channels in microglia (brain macrophages). Cell Physiol 44 (1998) C327-C342
89. Eder C. Regulation of microglial behavior by ion channel activity. J Neurosci Rev 81 (2005) 314-321
90. Escoubas P., Diochot S., Celerier M.L., Nakajima T., and Lazdunski M. Novel tarantula toxins for subtypes of voltage-dependent potassium channels in the Kv2 and Kv4 subfamilies. Mol Pharmacol 62 (2002) 48-57
91. Fäber K., and Kettenmann H. Physiology of microglial cells. Br Res Rev 48 (2005) 133-143
92. Faivre J.F., Calmels T.P., Rouanet S., Javre J.L., Cheval B., and Bril A. Characterisation of Kv4.3 in HEK293 cells: comparison with the rat ventricular transient outward potassium current. Cardiovasc Res 41 (1999) 188-199
93. + channel current. Circ Res 73 (1993) 210-216
94. Felts, and Smith. The use of potassium channel blocking agents in the therapy of demyelinating diseases. Ann Neurol 36 (1994) 454
95. Ferroni S., Planellscases R., Ahmed C.M.I., and Montal M. Expression of a genomic clone encoding a brain potassium channel in mammalian cells using lipofection. Eur Biophys J 21 (1992) 185-191
96. + currents of mouse dendritic cells. FEBS Lett 373 (1995) 127-130
97. + channel profile of microglia at immunologically defined functional states. Neuroscience 64 (1995) 183-191
98. Fletcher J.I., Wang X., Connor M., Christie M.J., King J.F., and Nicholson G.M. In: Darbon H., and Sabatier J.M. (Eds). Spider Toxins: A New Group of Potassium Channel Modulators (1999), Klewer/Escom, Dordrecht 61-69
99. Fordyce C.B., Jagasia R., Zhu X., and Schlichter L.C. Microglial Kv1.3 channels contribute to their ability to kill neurons. J Neurosci 25 (2005) 7139-7149
100. Frech G.C., VanDongen A.M., Schuster G., Brown A.M., and Joho R.H. A novel potassium channel with delayed rectifier properties isolated from rat brain by expression cloning. Nature 340 (1989) 642-645
101. Frick A., and Johnston D. Plasticity of dendritic excitability. J Neurobiol 64 (2004) 100-115
102. Fry M., Maue R.A., and Moody-Corbett F. Properties of Xenopus Kv1.10 channels expressed in HEK293 cells. J Neurobiol 60 (2004) 227-235
103. Fujihara K., and Miyoshi T. The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis. J Neurol Sci 159 (1998) 102-106
104. Gallin E.K. Calcium- and voltage-activated potassium channels human macrophages. Biophys J 46 (1984) 821-825
105. Gallin E.K. Ion channels in leukocytes. Physiol Rev 71 (1991) 775-811
106. Garcia M.L. Gate expectations. Nature 430 (2004) 153-155
107. Garcia M.L., Galvez A., Garcia-Calvo M., King V.F., Vazques J., and Kaczorowski G.J. Use of toxins to study potassium channels. J Bioenerg Biomembranes 23 (1991) 615-646
108. + channels from Leiurus quinquestriatus var. hebraeus venom. Biochemistry 33 (1994) 6834-6839
109. + channels. Toxicon 36 (1998) 1641-1650
110. Garcia M.L., Knaus H.-G., Leonard R.J., McManus O.B., Munujos P., Schmalhofer W.A., et al. Peptide toxins interacting with potassium channels. In: Soria B., and Ceña V. (Eds). Ion Channel Pharmacology (1998), Oxford University Press, Oxford 186-207
111. Garcia M.L., Gao Y.-D., McManus O.B., and Kaczorowski G.J. Potassium channels: from scorpion venoms to high-resolution structure. Toxicon 39 (2001) 739-748
112. Garcia-Calvo M., Leonard R.J., Novick J., Stevens S.P., Schmalhofer W., Kaczorowski G.J., et al. Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. J Biol Chem 268 (1993) 18866-18874
113. Gasparini S., Danse J.-M., Lecoq A., Pinkasfeld S., Zinn-Justin S., Young L.C., et al. Delineation of the functional site of α-dendrotoxin. J Biol Chem 273 (1998) 25393-25403
114. Gasparini S., Gilquin B., and Ménez A. Comparison of sea anemone and scorpion toxins binding to Kv1 channels: an example of convergent evolution. Toxicon 43 (2004) 901-908
115. Gazarian K.G., Gazarian T., Hernández R., and Possani L.D. Immunology of scorpion toxins and perspectives for generation of anti-venom vaccines. Vaccine 23 (2005) 3357-3368
116. + channel subunit Kv2.2 in brain stem and hypothalamic neurons. Circ Res 84 (1999) 352-359
117. Gilquin B., Braud S., Eriksson M.A.L., Roux B., Bailey T.D., Priest B.T., et al. A variable residue in the pore of Kv1 channels is critical for the high affinity of blockers from sea anemones and scorpions. J Biol Chem 280 (2005) 27093-27102
118. Gimenez-Gallego G., Navia M.A., Reuben J.P., Katz G.M., Kaczorowski G.J., and Garcia M.L. Purification, sequence, and model structure of charybdotoxin, a potent selective inhibitor of calcium-activated potassium channels. Proc Natl Acad Sci U S A 85 (1988) 3329-3333
119. Gledhill R.F., and McDonald W.I. Morphological characteristics of central demyelination and remyelination: a single-fiber study. Ann Neurol 1 (1977) 552-560
120. + channel: peptide and channel residues mediating molecular recognition. Neuron 12 (1994) 1377-1388
121. Goodman A.D., Blight A., Cohen J.A., et al. Placebo-controlled double-blinded dose ranging study of Fampridine-SR in multiple sclerosis. Mult Scler 8 Suppl. 1 (2002) S116 (P308)
122. Goodman A.D., Cohen J., Vollmer T., Johnson M., Cohen R., and Katz M. Phase 2 trial of Fampridine-SR in multiple sclerosis. Mult Scler 10 Suppl. 2 (2004) S273 (P695)
123. + channels in T lymphocytes. Biophys J 55 (1989) 203-206
124. + channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45 (1994) 1227-1234
125. Grupe A., Schroter K.H., Ruppersberg J.P., Stocker M., Drewes T., Beckh S., et al. Cloning and expression of a human voltage-gated potassium channel. A novel member of the RCK potassium channel family. EMBO J 9 (1990) 1749-1756
126. Gu C., Jan Y.N., and Jan L.Y. A conserved domain in axonal targeting of Kv1 (Shaker) voltage-gated potassium channels. Science 301 (2003) 646-649
127. + channels. Science 289 (2000) 123-127
128. Gutman G.A., Chandy K.G., Adelman J.P., Aiyar J., Bayliss D.A., Clapham D.E., et al. International union of pharmacology: XLI. Compendium of voltage-gated ion channels: potassium channels. Pharm Rev 55 (2003) 583-586
129. Guy H.R. Models of voltage- and transmitter-activated channels based on their amino acid sequences. In: Pasternack C.A. (Ed). Monovalent Cations in Biological Systems (1990), CRC, Boca Raton 31-58
130. Guy H.R., and Seetharamulu P. Molecular model of the action potential sodium channel. Proc Natl Acad Sci U S A 83 (1986) 508-512
131. Halliwell J.V., Othman I.B., Pelchen-Matthews A., and Dolly J.O. Central action of dendrotoxin selective reduction of a transient K conductance in hippocampus and binding to localized acceptors. Proc Natl Acad Sci U S A 83 (1986) 493-497
132. Hamill O.P., Marty A., Neher E., Sakmann B., and Sigworth F.J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 391 (1981) 85-100
133. Harvey A.L. Twenty years of dendrotoxins. Toxicon 39 (2001) 15-26
134. Harvey A.L., and Anderson A.J. Dendrotoxins: snake toxins that block potassium channels and facilitate neurotransmitter release. Pharmacol Ther 31 (1985) 33-55
135. Harvey A.L., and Gage P.W. Increase of evoked release of acetylcholine at the neuromuscular junction by a fraction from the venom of the eastern green mamba snake (Dendroaspis angusticeps). Toxicon 19 (1981) 373-381
136. Harvey A.L., and Karlsson E. Dendrotoxin from the venom of the green mamba, Dendroaspis angusticeps: a neurotoxin that enhances acetylcholine release at neuromuscular junctions. Arch Pharmacol 312 (1980) 1-6
137. Harvey A.L., and Karlsson E. Protease inhibitor homologues from mamba venoms: facilitation of acetylcholine release and interactions with prejunctional blocking toxins. Br J Pharmacol 77 (1982) 133-161
138. Hayes K.C. 4-aminopyridine and spinal cord injury: a review. Restor Neurol Neurosci 6 (1994) 259-270
139. + channel pore through mutant cycles with a peptide inhibitor. Science 268 (1995) 307-310
140. Hildebrand C., and Mohseni S. The structure of myelinated axons in the CNS. In: Waxman S. (Ed). Multiple Sclerosis as a Neuronal Disease (2005), Elsevier Academic Press, Amsterdam 1-28
141. Hille B. Ionic Channels in Excitable Membranes. 3rd ed. (2001), Sinauer, Sunderland
142. Hlubek M.D., and Cobbett P. Differential effects of K(+) channel blockers on frequency-dependent action potential broadening in supraoptic neurons. Brain Res Bull 53 (2000) 203-209
143. Ho W.K., Kim I., Lee C.O., Youm J.B., Lee S.H., and Earn Y.E. Blockade of HERG channels expressed in Xenopus laevis oocytes by external divalent cations. Biophys J 76 (1999) 1959-1971
144. Hodgkin A.L. Evidence for electrical transmission in nerve. I. J Physiol (Lond) 90 (1937) 183-210
145. Hodgkin A.L. Evidence for electrical transmission in nerve. II. J Physiol (Lond) 90 (1937) 211-232
146. Hodgkin A.L. Evidence for electrical transmission in nerve: part I. J Physiol 90 (1952) 183-210
147. Hodgkin A.L. Evidence for electrical transmission in nerve: part II. J Physiol 90 (1952) 211-232
148. Hodgkin A.L., and Huxley A.F. Action potentials recorded from inside a nerve fibre. Nature 144 (1939) 710-711
149. Hodgkin A.L., and Huxley A.F. Resting and action potentials in single nerve fibres. J Physiol 104 (1945) 176-195
150. Hodgkin A.L., and Huxley A.F. A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol 117 (1952) 500-544
151. Hodgkin A.L., Huxley A.F., and Katz B. Ionic currents underlying activity in the giant axon of the squid. Arch Sci Physiol 3 (1949) 129-150
152. + current. Am J Physiol Heart Circ Physiol 278 (2001) H295-H299
153. Hoshi T., Zagotta W.N., and Aldrich R.W. Biophysical and molecular mechanisms of Shaker potassium channel inactivation. Science 250 (1990) 533-538
154. Hurst R.S., Busch A.E., Kavanaugh M.P., Osborne P.B., North R.A., and Adelman J.P. Identification of amino acid residues involved in dendrotoxin block of rat voltage-dependent potassium channels. Mol Pharmacol 40 (1991) 572-576
155. Huxley A.F. Electrical activity of nerve: the background up to 1952. In: Waxman S.G., Kocsis J.D., and Stys P.K. (Eds). The Axon: Structure, Function and Pathophysiology (1995), Oxford University Press, New York 3-10
156. Huxley A.F. Hodgkin and the action potential. J Physiol (Lond) 538 (2002) 2
157. Huxley A.F., and Stämpfli R. Evidence for saltatory conduction in peripheral myelinated nerve fibres. J Physiol (Lond) 108 (1949) 315-339
158. + and HERG currents. Biochem J 378 (2004) 745-752
159. Imredy J.P., and MacKinnon R. Energetic and structural interactions between δ-dendrotoxin and a voltage-gated potassium channel. J Mol Biol 296 (2000) 1283-1294
160. + channel. Nature 353 (1991) 86-90
161. + channel inactivation gating. In: Pinchon Y. (Ed). Comparative Molecular Neurobiology (1993), Birchauser Verlag, Basel, Switzerland 338-351
162. IUPHAR Compendium of Voltage-Gated Ion Channels. (2002). Retrieved from http://www.iuphar-db.org/iuphar-ic/ and http://www.iuphar-db.org/iuphar-ic/KV.html.
163. Jan L.Y. Studies of voltage-dependent and inwardly rectifying potassium channels. In: Kurachi Y., Jan L.Y., and Lazdunski M. (Eds). Potassium Ion Channels Molecular Structure, Function, and Diseases (1999), Academic Press, San Diego 9-27
164. Jerng H.H., Shahidullah M., and Covarrubias M. Inactivation gating of Kv4 potassium channels: molecular interactions involving the inner vestibule of the pore. J Gen Physiol 113 (1999) 641-660
165. Jerng H.H., Pfaffinger P.J., and Covarrubias M. Molecular physiology and modulation of somatodendritic A-type potassium channels. Mol Cell Neurosci 27 (2004) 343-369
166. + channel. Nature 423 (2003) 42-48
167. + channel. Nature 423 (2003) 33-41
168. Jones R.E., Heron J.R., Foster D.H., Sneglar R.S., and Mason R.J. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 60 (1983) 353-362
169. + channels. Toxicon 43 (2004) 909-914
170. Judge S.I.V., Monteiro M.J., Yeh J.Z., and Bever Jr. C.T. Inactivation gating and 4-AP sensitivity in human brain Kv1.4 potassium channel. Brain Res 831 (1999) 43-54
171. + channel: phenylalanine substitutions in leucine heptad repeat region stabilize channel closed state. Mol Pharmacol 61 (2002) 913-920
172. Judge, S. I. V., Bever, C. T. Jr., & Hoffman, P. M. (in press). Voltage-gated potassium channels in multiple sclerosis: overview and new implications for treatment of CNS inflammation and degeneration. J Rehabil Res Dev.
173. Jungo F., and Bairoch A. Tox-Prot, the toxin protein annotation program of the Swiss-Prot protein knowledgebase. Toxicon 45 (2005) 293-301
174. Kagawa T., Ikenaka K., Inoue Y., Kuriyama S., Tsujii T., Nakao J., et al. Glial cell degeneration and hypomyelination caused by overexpression of myelin proteolipid protein gene. Neuron 13 (1994) 427-442
175. Kalman K., Nguyen A., Tseng-Crank J., Dukes I.D., Chandy G., Hustad C.M., et al. Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7. J Biol Chem 273 (1998) 5851-5857
176. Kalman K., Pennington M.W., Lanigan M.D., Nguyen A., Rauer H., Mahnir V., et al. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem 273 (1998) 32697-32707
177. Kamb A., Iverson L.E., and Tanouye M.A. Molecular characterization of Shaker, a Drosophila gene that encodes a potassium channel. Cell 50 (1987) 405-413
178. Kamb A., Tseng-Crank J., and Tanouye M.A. Multiple products of the Drosophila Shaker gene may contribute to potassium channel diversity. Neuron 1 (1988) 421-430
179. Kehl S.J., Eduljee C., Kwan D.C., Zhang S., and Fedida D. Molecular determinants of the inhibition of human Kv1.5 potassium currents by external protons and Zn(2+). J Physiol 541 (2002) 9-24
180. Kem W.R., Pennington M.W., and Norton R.S. Sea anemone toxins as templates for the design of immunosuppressant drugs. In: Darbon H., and Sabatier J.M. (Eds). Perspectives in Drug Discovery and Design: Animal Toxins and Potassium Channels (1999), Klewer/Escom, Dordrecht 111-129
181. Kerr P.M., Clement-Chomienne O., Thorneloe K.S., Chen T.T., Ishii K., Sontag D.P., et al. Heteromultimeric Kv1.2-Kv1.5 channels underlie 4-aminopyridine-sensitive delayed rectifier K(+) current of rabbit vascular myocytes. Circ Res 89 (2001) 1038-1044
182. Kharrat R., Mansuelle P., Sampieri F., Crest M., Oughideni R., Van Rietschoten J., et al. Maurotoxin, a four disulfide bridge toxin from Scorpio maurus venom: purification, structure and action on potassium channels. FEBS Lett 406 (2005) 284-290
183. Kirsch G.E., and Drewe J.A. Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels. J Gen Physiol 102 (1993) 797-816
184. Kirsch G.E., and Narahashi T. Site of action and active form of aminopyridines in squid axon membranes. J Pharmacol Exp Ther 226 (1983) 174-179
185. Kirsch G.E., Yeh J.Z., and Oxford G.S. Modulation of aminopyridine block of potassium currents in squid axon. Biophys J 50 (1986) 637-644
186. + channels. FEBS Lett 278 (1991) 55-60
187. + channels determined by an interacting pair of nonpolar amino acids. Neuron 8 (1992) 499-505
188. + pores. Neuron 11 (1993) 503-512
189. + at the potassium channel selectivity filter. Biophys J 74 (1998) 1840-1849
190. Kiss T., László Z., and Szabadics J. Mechanism of 4-aminopyridine block of the transient outward K-current in identified Helix neuron. Brain Res 927 (2002) 168-179
191. Kocsis J.D., and Waxman S.G. Absence of potassium conductance in central myelinated neurons. Nature 287 (1980) 348-349
192. Kocsis J.D., and Waxman S.G. Action potential electrogenesis in mammalian central axons. Adv Neurol 31 (1981) 299-312
193. + channel, rat Kv1.4, has two potential domains that could produce rapid inactivation. J Biol Chem 272 (1997) 19333-19338
194. Koo G.C., Blake J.T., Talento A., Nguyen M., Lin S., Sirotina A., et al. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol 158 (1997) 5120-5128
195. Koschak A., Bugianesi R.M., Mitterdorfer J., Kaczorowski G.J., Garcia M.L., and Knauss H.G. Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from Centruroides limbatus venom. J Biol Chem 273 (1998) 2639-2644
196. Kotecha S.A., and Schlichter L.C. A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation. J Neurosci 19 (1999) 10680-10693
197. Krupp L.B., LaRocca N.G., Muir-Nash J., and Steinberg A.D. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosis. Arch Neurol 46 (1989) 1121-1123
198. Kuo A., Gulbis J.M., Antcliff J.F., Rahman T., Lowe E.D., Zimmer J., et al. Crystal structure of the potassium channel KirBac1.1 in the closed state. Science 300 (2003) 1922-1926
199. Kurachi Y., Jan L.Y., and Lazdunski M. Potassium Ion Channels: Molecular Structure, Function, and Disease (1999), Academic Press, San Diego
200. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol 33 (1983) 1444-1452
201. + concentration and mutations in the outer pore mouth affect the inhibition of Kv1.5 current by Ni2+. Biophys J 86 (2004) 2238-2250
202. Lang R., Lee G., Liu W., Tian S., Rafi H., Orias M., et al. KCNA10: a novel ion channel functionally related to both voltage-gated potassium and CNG cation channels. Am J Physiol Renal Physiol 278 (2000) 1013-1021
203. Lang R.J., Mulholland E., and Exintaris B. Characterization of the ion channel currents in single myocytes of the guinea pig prostate. J Urol 172 (2004) 1179-1187
204. + channels, isolated from Heterometrus spinnifer (Scorpionidae) venom. Biochem J 328 (1997) 321-327
205. Lee S.-Y., and MacKinnon R. A membrane-access mechanism of ion channel inhibition by voltage sensor toxins from spider venom. Nature 430 (2004) 232-235
206. Legros C., Celerier M.L., Henry M., and Guette C. Nanospray analysis of the venom of the tarantula Theraphosa leblondi: a powerful method for direct venom mass fingerprinting and toxin sequencing. Rapid Commun Mass Spectrom 18 (2004) 1024-1034
207. Lemeignan M., Chanelet J., and Saade N.E. Etude del'action d'un convulsivant special (la 4-aminopyridine) sur les nerfs de vertebras. (in French). C R Seances Soc Biol 163 (1969) 359-365
208. Lewis R.J., and Garcia M.L. Therapeutic potential of venom peptides. Nat Rev Drug Discov 2 (2003) 790-802
209. Lien C.C., Martina M., Schultz J.H., Ehmke H., and Jonas P. Gating, modulation and subunit composition of voltage-gated K(+) channels in dendritic inhibitory interneurones of rat hippocampus. J Physiol 538 (2002) 405-419
210. + channels. Proc Natl Acad Sci U S A 95 (1998) 8585-8589
211. + channel during gating. Neuron 16 (1996) 859-867
212. Loboda A., and Armstrong C.M. Resolving the gating charge movement associated with late transitions in K channel activation. Biophys J 81 (2001) 905-916
213. + channel. Science 309 (2005) 897-903
214. Long S.B., Campbell E.B., and MacKinnon R. Voltage sensor of Kv1.2: structural basis of electromechanical coupling. Science 309 (2005) 903-908
215. +-channel drk1. J Mol Recognit 15 (2002) 175-179
216. +-channels. J Mol Recognit 16 (2003) 392-395
217. Ludwin S.K. Pathology of demyelination and remyelination. In: Waxman S.G., and Ritchie J.M. (Eds). Demyelinating Diseases Basic and Clinical Electrophysiology. Advances in Neurology vol. 31 (1981), Raven Press, New York 123-168
218. Ludwin S.K. Pathology of the myelin sheath. In: Waxman S.G., Kocsis J.D., and Stys P.K. (Eds). The Axon: Structure, Function and Pathophysiology (1995), Oxford University Press, New York 412-437
219. + channel diversity in the mammalian central nervous system. Proc Natl Acad Sci U S A 88 (1991) 3932-3936
220. + channel. J Gen Physiol 91 (1988) 335-349
221. MacKinnon R., and Miller C. Mutant potassium channels with altered binding of charybdotoxin, a pore-blocking peptide inhibitor. Science 245 (1989) 1382-1385
222. + channels share common structural features. Neuron 1 (1988) 997-1001
223. MacKinnon R., Heiginbotham R.L., and Abramson T. Mapping the receptor site for charybdotoxin, a pore-blocking potassium channel inhibitor. Neuron 5 (1990) 767-771
224. Magee J.C., and Johnston D. Plasticity of dendritic function. Curr Opin Neurobiol 15 (2005) 334-342
225. Mainero C., Inghilleri M., Pantano P., Conte A., Lenzi D., Frasca V., et al. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Neurol 62 (2004) 2044-2050
226. Markovic-Plese S., and McFarland H.F. Immunopathogenesis of the multiple sclerosis lesion. Curr Neurol Neurosci Rep 1 (2001) 257-262
227. Martin R., McFarland H.F., and McFarlin D.E. Immunological aspects of demyelinating diseases. Annu Rev Immunol 10 (1992) 153-187
228. Martin R., Bielekova B., Gran B., and McFarland H.F. Lessons from studies of antigen-specific T cell responses in Multiple Sclerosis. J Neural Transm Suppl 60 (2000) 361-373
229. Martin R., Stürzebecher C.S., and McFarland H.F. Immunotherapy of multiple sclerosis: where are we? Where should we go?. Nat Immunol 2 (2001) 785-788
230. + channels. Eur J Biochem 270 (2003) 3583-3592
231. McCormack K., Campanelli J.T., Ramaswani M., Matthew M.K., and Tanouye M.A. Leucine-zipper motif update. Nature 340 (1989) 103
232. + channels. Proc Natl Acad Sci U S A 88 (1991) 2931-2935
233. + channels. Neuron 12 (1994) 301-315
234. McFarlin, D. E., & McFarland, H. F. (1982). Multiple sclerosis. N Engl J Med, 307, 1183-1188, 1246-1251.
235. Ménez A. Functional architectures of animal toxins: a clue to drug design?. Toxicon 36 (1998) 1557-1572
236. Middleton R.E., Sanchez M., Linde A.R., Bugianesi R.M., Dai G., Felix J.P., et al. Substitution of a single residue in Stichodactyla helianthus peptide, ShK-Dap22, reveals a novel pharmacological profile. Biochemistry 42 (2003) 13698-13707
237. + channel-blocking peptides. Neuron 15 (1995) 5-10
238. + channels from mammalian skeletal muscle. Nature 313 (1985) 316-318
239. Misonou H., Mohapatra D.P., Park E.W., Leung V., Zhen D., Misonou K., et al. Regulation of ion channel localization and phosphorylation by neuronal activity. Nat Neurosci 7 (2004) 711-718
240. Molgo J., Lundh H., and Thesleff S. Potency of 3,4-diaminiopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 11 (1980) 25-34
241. Moore J.W. Voltage clamp studies on internally perfused axons. J Gen Physiol 48 (1965) 11-17
242. Morell P. Myelin. 2nd ed. (1984), Plenum Press, New York
243. Mouhat S., Jouirou B., Mosbah A., De Waard M., and Sabatier J.-M. Diversity of folds in animal toxins acting on ion channels. Biochem J 378 (2004) 717-726
244. Mouhat S., Mosbah A., Visan V., Wulff H., Delepierre M., Darbon H., et al. The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. Biochem J 377 (2004) 25-36
245. + channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J 385 (2005) 95-104
246. e Colloque de la Société des neurosciences, Lille 2005, I.1.
247. + channels of Kv1.5 and Kv1.3. [abstract]. Rare Neuroimmunologic Disorders Symposium, Baltimore, MD (2004)
248. Narahashi T., Moore J.W., and Scott W.R. Tetrodotoxin blockage of sodium conductance increase in lobster giant axons. J Gen Physiol 47 (1964) 965-974
249. + channels after chronic spinal cord injury. Eur J Neurosci 12 (2000) 491-506
250. Neher E., and Sakmann B. Single channel currents recorded from membrane of denervated frog muscle fibres. Nature 260 (1976) 799-802
251. Noda M., Ikeda T., Kayano T., Suzuki H., Takeshima H., Kurasaki M., et al. Existence of distinct sodium channel messenger RNA's in rat brain. Nature 320 (1986) 188-192
252. Noda M., Ikeda T., Suzuki H., Takeshima H., Takahashi T., Kuno M., et al. Expression of functional sodium channels from cloned cDNA. Nature 322 (1986) 826-828
253. North R.A. Handbook of Receptors and Channels: Ligand and Voltage-Gated Ion Channels (1995), CRC Press, Ann Arbor, MI
254. Norton W.T., and Cammer W. Chemical pathology if diseases involving myelin. In: Morell P. (Ed). Myelin. 2nd ed. (1984), Plenum Press, New York 369-403
255. Nunoki K., Ishii K., Okada H., Yamagishi T., Murakoshi H., and Taira N. Hybrid potassium channels by tandem linkage of inactivating and non-inactivating subunits. J Biol Chem 269 (1994) 24138-24142
256. Okada M., Wada K., Kamata A., Murakami T., Zhu G., and Kaneko S. Impaired M-current and neuronal excitability. Epilepsia 43 (2002) 36-38
257. Olamendi-Portugal T., Somodi S., Fernández J.A., Zamudio F.Z., Becerril B., Varga Z., et al. Novel alpha-KTx peptides from the venom of the scorpion Centruroides elegans selectively blockade Kv1.3 over IKCa1 K(+) channels of T cells. Toxicon 46 46 (2005) 418-429
258. Olivera B.M., and Cruz L.J. Conotoxins, in retrospect. Toxicon 39 (2001) 7-14
259. Ouadid-Ahidouch H., Chaussade F., Roudbaraki M., Slomianny C., Dewailly E., Delcourt P., et al. Kv1.1 K(+) channels identification in human breast carcinoma cells: involvement in cell proliferation. Biochem Biophys Res Commun 278 (2000) 272-277
260. + channel, mKv1.1 (MK-1), when stably transfected in Chinese hamster ovary cells. Br J Pharmacol 120 (1997) 1029-1034
261. + channel cloned from mammalian brain. Proc Natl Acad Sci U S A 88 (1991) 4386-4390
262. Papazian D.M., Schwarz T.L., Tempel B.L., Jan Y.N., and Jan L.Y. Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila. Science 237 (1987) 749-753
263. Peles E., and Salzer J.L. Molecular domains of myelinated axons. Curr Opin Neurobiol 10 (2000) 558-565
264. Pelhate M., and Pichon Y. Proceedings: selective inhibition of potassium current in the giant axon of the cockroach. J Physiol 242 (1974) 90P-91P
265. Pelhate M., Hue B., and Chanelet J. Modifications by 4 amino-pyridine of electric characteristics of the isolated giant axon of an insect, the cockroach (Periplaneta americana L.). (in French). C R Seances Soc Biol Fil 168 (1974) 27-34
266. Pender M.P. Conduction block due to demyelination at the ventral root exit zone in experimental allergic encephalomyelitis. Brain Res 367 (1986) 398-401
267. Pennington M.W., Byrnes M.E., Zaydenberg I., Khaytin I., de Chastonay J., Krafte D.S., et al. Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone. Int J Protein Res 46 (1995) 354-358
268. Perchenet L., and Clement-Chomienne O. External nickel blocks human Kv1.5 channels stably expressed in CHO cells. J Membr Biol 183 (2001) 51-60
269. Perreault P., and Avoli M. Physiology and pharmacology of epileptiform activity induced by 4-aminopyridine in rat hippocampal slices. J Neurophysiol 65 (1991) 771-785
270. Perry V.H., and Phil D. Inflammation and axon degeneration. In: Waxman S. (Ed). Multiple Sclerosis as a Neuronal Disease (2005), Elsevier Academic Press, Amsterdam 241-253
271. Po S., Roberds S., Snyders D.J., Tamkun M.M., and Bennett P.B. Heteromultimeric assembly of human potassium channels. Molecular basis of a transient outward current?. Circ Res 72 (1993) 1326-1336
272. Polman C.H., Bertelsmann F.W., VanLoenen A.C., and Koetsier J.C. 4-aminopyridine in the treatment of patients with multiple sclerosis: long term efficacy and safety. Arch Neurol 51 (1994) 292-296
273. Polman C.H., Bertelsmann F.W., DeWaal R., et al. 4-aminopyridine is superior to 3,4 diaminopyridine in the treatment of multiple sclerosis. Arch Neurol 51 (1994) 1136-1139
274. Pongs O. Molecular biology of voltage-dependent potassium channels. Physiol Rev 72 (1992) S69-S88
275. Pongs O., Kecskemethy N., Muller R., Krah-Jentgens I., Baumann A., Kiltz H.H., et al. Shaker encodes a family of putative potassium channel proteins in the nervous system of Drosophila. EMBO J 7 (1988) 1087-1096
276. + channels blocking peptide, purified from the venom of the scorpion Centruroides noxius Hoffmann. Carlsberg Res Commun 47 (1982) 285-289
277. +-channels. In: Darbon H., and Sabatier J.M. (Eds). Perspectives in Drug Discovery and Design: Animal Toxins and Potassium Channels (1999), Klewer/Escom, Dordrecht 15-40
278. Prineas J.W., and Wright R.G. Macrophages, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 38 (1978) 409-418
279. Raine C.S. Morphology of myelin and myelination. In: Morell P. (Ed). Myelin. 2nd ed. (1984), Plenum Press, New York 1-50
280. Raine C.S. Neuropathology of myelin disorders. In: Morell P. (Ed). Myelin. 2nd ed. (1984), Plenum Press, New York 259-310
281. Raine C.S. The Dale E. McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 36 (1994) 61-72
282. Rao S.M., Leo G.J., Ellington L., Nauertz T., Bernardin L., and Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns and prediction. Neurology 41 (1991) 685-691
283. Rasband M.N. It's "juxta" potassium channel!. J Neurosci Res 76 (2004) 749-757
284. Rasband M.N. Potassium channel organization of myelinated and demyelinated axons. In: Waxman S. (Ed). Multiple Sclerosis as a Neuronal Disease (2005), Elsevier Academic Press, Amsterdam 57-67
285. Rasband M.N., and Shrager P. Ion channel sequestration in central nervous system axons. J Physiol 525 (2000) 63-73
286. Rasband M.N., and Trimmer J.S. Developmental clustering of ion channels at and near the node of Ranvier. Dev Biol 236 (2001) 5-16
287. + channels in spinal cord. J Comp Neurol 429 (2001) 166-176
288. Rasband M.N., Trimmer J.S., Schwarz T.L., Levinson S.R., Ellisman M.H., Schachner M., et al. Potassium channel distribution, clustering, and function in remyelinating rat axons. J Neurosci 18 (1998) 36-47
289. + channel distribution and clustering in developing and hypomyelinated axons of the optic nerve. J Neurocytol 28 (1999) 319-331
290. Rasminsky M., and Sears T.A. Internodal conduction in undissected demyelinated nerve fibres. J Physiol 227 (1972) 323-350
291. + (Kv1.4) channel. Adv Exp Med Biol 382 (1995) 11-22
292. + channel (Kv1.4) cloned from ferret ventricle and expressed in Xenopus oocytes. J Physiol (Lond) 485 (1995) 59-71
293. Regaya I., Beeton C., Ferrat G., Andreotti N., Darbon H., De Waard M., et al. Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins. J Biol Chem 279 (2004) 55690-55696
294. + channels of the mammalian brain. FASEB J 5 (1991) 164-170
295. + channel β subunits: expression and distribution of Kvβ1 and Kvβ2 in adult rat brain. J Neurosci 16 (1996) 4846-4860
296. + channel complexes. J Neurosci 17 (1997) 8246-8258
297. Ritchie J.M. Potassium channels in regenerating and immature rabbit myelinated nerve. J Physiol 322 (1981) 20P
298. Ritchie J.M. Sodium and potassium channels in regenerating and developing mammalian myelinated nerve fibres. Proc R Soc Lond 215 (1982) 273-287
299. Ritchie J.M. Physiological basis of conduction in myelinated nerve fibers. In: Morell P. (Ed). Myelin. 2nd ed. (1984), Plenum Press, New York 1145-1171
300. Ritchie J.M. Physiology of axons. In: Waxman S.G., Kocsis J.D., and Stys P.K. (Eds). The Axon: Structure, Function and Pathophysiology (1995), Oxford University Press, New York 68-96
301. Ritchie J.M., and Chiu S.Y. Distribution of sodium and potassium channels in mammalian myelinated nerve. In: Waxman S.G., and Ritchie J.M. (Eds). Demyelinating Diseases Basic and Clinical Electrophysiology. Advances in Neurology vol. 31 (1981), Raven Press, New York 329-342
302. Roberds S.L., and Tamkun M.M. Cloning and tissue-specific expression of five voltage-gated potassium channel cDNAs expressed in rat heart. Proc Natl Acad Sci U S A 88 (1991) 1798-1802
303. Robertson B., and Owen D.G. Pharmacology of a cloned potassium channel from mouse brain (MK-1) expressed in CHO cells: effects of blockers and an 'inactivation peptide'. Br J Pharmacol 109 (1993) 725-735
304. + channels. Toxicin 36 (1998) 1609-1611
305. +-channels. Toxicon 43 (2004) 865-875
306. + channels. Mol Pharmacol 50 (1996) 1167-1177
307. Rossini P.M., Pasqualetti P., Pozzilli C., Grasso M.G., Millefiorini E., Graceffa A., et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 7 (2001) 354-358
308. Rudy B. Diversity and ubiquity of K channels. J Neurosci 25 (1988) 729-749
309. Rudy B. Molecular diversity of ion channels and cell function. Ann N Y Acad Sci 868 (1999) 1-12
310. Rudy B., Chow A., Lau D., Amarillo Y., Ozaita A., Saganich M., et al. Contributions of Kv3 channels to neuronal excitability. Ann N Y Acad Sci 868 (1999) 304-343
311. Ruppersberg J.P., Schroter K.H., Sakmann B., Stocker M., Sewing S., and Pongs O. Heteromultimeric channels formed by rat brain potassium-channel proteins. Nature 345 (1990) 535-537
312. Ruppersberg J.P., Frank R., Pongs O., and Stocker M. Cloned neuronal I-KA channels reopen during recovery from inactivation. Nature 353 (1991) 657-660
313. Rus H., Pardo C.A., Hu L., Darrah E., Cudrici C., and Niculescu T. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A 102 (2005) 11094-11099
314. + current expressed in Xenopus oocytes. J Physiol 481 (1994) 571-584
315. Ruta V., and MacKinnon R. Localization of the voltage-sensor toxin receptor on KvAP. Biochemistry 43 (2004) 10071-10079
316. + channel. Nature 422 (2003) 180-185
317. Sack J.T., Aldrich R.W., and Gilly W.F. A gastropod toxin selectivity slows early transitions in the Shaker K channel's activation pathway. J Gen Physiol 123 (2004) 685-696
318. Sakmann B., and Neher E. Single-Channel Recording. 2nd ed. (1995), Plenum Press, New York
319. + channels conserved in flies, mice and humans. Trends Neurosci 15 (1992) 161-166
320. Salkoff L., Kundel M.T., Wang Z.-W., Butler A., Yuan A., Nonet M., et al. The impact of the Caenorhabditis elegans genome project on potassium channel biology. In: Kurachi Y., Jan L.Y., and Lazdunski M. (Eds). Potassium Ion Channels Molecular Structure, Function, and Diseases (1999), Academic Press, San Diego 9-27
321. Sanchez-Chapula J.A., and Sanguinetti M.C. Altered gating of HERG potassium channels by cobalt and lanthanum. Pflügers Arch 440 (2000) 264-274
322. Sanguinetti M.C., Johnson J.H., Hammerland L.G., Kelbaugh P.R., Volkmann R.A., Saccomano N.A., et al. Heteropodatoxins: peptides isolated from spider venom that block Kv4.2 potassium channels. Mol Pharmacol 51 (1997) 491-498
323. Sansom M.S.P., Shrivastava I.H., Bright J.N., Tate J., Capener C.E., and Biggin P.C. Potassium channels: structures, models, simulations. Biochim Biophys Acta 1565 (2002) 294-307
324. Savarin P., Guenneugues M., Gilquin B., Lamthanh H., Gasparini S., Zinn-Justin S., et al. Three-dimensional structure of κ-Conotoxin PVIIA, a novel potassium channel-blocking toxin from cone snails. Biochemistry 37 (1998) 5407-5416
325. Scherer S.S., and Arroyo E.J. Recent progress on the molecular organization of myelinated axons. J Peripher Nerv Syst 7 (2002) 1-12
326. Schmalz F., Kinsella J., Koh S.D., Vogalis F., Schneider A., Flynn E.R., et al. Molecular identification of a component of delayed rectifier current in gastrointestinal smooth muscles. Am J Physiol 274 (1998) G901-G911
327. + channel analyzed by NMR spectroscopy. Eur Biophys J 27 (1998) 99-104
328. Schwarz T.L., Tempel B.L., Papazian D.M., Jan Y.N., and Jan L.Y. Multiple potassium-channel components are produced by alternative splicing at the Shaker locus in Drosophila. Nature 331 (1988) 137-142
329. Schwid S.R., Petrie M.D., McDermott M.P., Tierney D.S., Mason D.H., and Goodman A.D. Quantitative assessment of sustained release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 48 (1997) 817-821
330. Sears T.A., and Bostock H. Conduction failure in demyelination: is it inevitable?. In: Waxman S.G., and Ritchie J.M. (Eds). Demyelinating Diseases Basic and Clinical Electrophysiology. Advances in Neurology vol. 31 (1981), Raven Press, New York 357-375
331. + channels operating at subthreshold potentials with unique expression in heart and brain. J Neurophysiol 75 (1996) 2174-2179
332. Service R.F. A new portrait puts potassium pore in a fresh light. Science 309 (2005) 867
333. Shapiro B.I. Effects of strychnine on the potassium conductance of the frog node of Ranvier. J Gen Physiol 69 (1977) 897-914
334. Sheean G.L., Murray N.M.F., Rothwell J.C., Miller D.H., and Thompson J.A. An open labeled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 121 (1998) 967-975
335. + channel proteins in rat central neurons. Neuron 9 (1992) 271-284
336. + channel subunit in different neurons of rat brain. J Neurosci 14 (1992) 2408-2417
337. + channels detected in vivo. Nature 365 (1993) 72-75
338. Sherratt R.M., Bostock H., and Sears T.A. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 283 (1980) 570-572
339. + channel surface expression through effects early in biosynthesis. Neuron 16 (1996) 843-852
340. + channels. Biophys J 67 (1994) 2316-2325
341. Shieh C.-C., Coghlan M., Sullivan J.P., and Gopalakrishnan M. Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 52 (2000) 557-593
342. Shrager P. Action potential conduction recorded optically in normal, demyelinated, and remyelinating axons. In: Waxman S.G., Kocsis J.D., and Stys P.K. (Eds). The Axon: Structure, Function and Pathophysiology (1995), Oxford University Press, New York 341-352
343. Shrager P., and Wu J.V. Ionic channels of myelinated nerve. In: Peracchia C. (Ed). Handbook of Membrane Channels Molecular and Cellular Physiology (1994), Academic Press, San Diego 105-113
344. Shrivastava I.H., Durell S.R., and Guy H.R. A model of voltage gating developed using the KvAP channel crystal structure. Biophys J 87 (2004) 2255-2270
345. Silveira R., Barbeito L., and Dajas F. Behavioral and neurochemical effects of intraperitoneally injected dendrotoxin. Toxicon 26 (1988) 287-292
346. Silveira R., Siciliano J., Abo V., Viera L., and Dajas F. Intrastriatal dendrotoxin injection: behavioral and neurochemical effects. Toxicon 26 (1988) 1009-1015
347. Slessinger P.A., Jan Y.N., and Jan L.Y. The S4-S5 loop contributes to the ion-selective pore of potassium channels. Neuron 11 (1993) 739-749
348. Smart S.L., Lopantsev V., Zhang C.L., Robbins C.A., Wang H., Chiu S.Y., et al. Deletion of the K(V)1.1 potassium channel causes epilepsy in mice. Neuron 20 (1998) 809-819
349. Smith C., Phillips M., and Miller C. Purification and properties of charybdotoxin. J Biol Chem 261 (1986) 14607-14613
350. Smith K.J., and Hall S.M. Nerve conduction during peripheral demyelination and remyelination. J Neurol Sci 48 (1980) 201-219
351. Smith K.J., and Waxman S.G. The conduction properties of demyelinated and remyelinated axons. In: Waxman S. (Ed). Multiple Sclerosis as a Neuronal Disease (2005), Elsevier Academic Press, Amsterdam 85-100
352. Smith K.J., Felts P.A., and John G.R. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 123 (2000) 171-184
353. Smits R.C.F., Emmen H.H., Bertelsmann F.W., Kulig B.M., van Loenen A.C., and Polman C.H. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 44 (1994) 1701-1705
354. Snyders D.J., Tamkun M.M., and Bennett P.B. A rapidly activating and slowly inactivating potassium channel cloned from human heart-functional analysis after stable mammalian cell culture expression. J Gen Physiol 101 (1993) 513-543
355. Solari A., Uidehaag B., Giuliani G., Pucci E., and Taus C. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev 2 (2003) (CD001330)
356. Song W.J., Tkatch T., Baranauskas G., Ichinohe N., Kitai S.T., and Surmeier D.J. Somatodendritic depolarization-activated potassium currents in rat neostriatal cholinergic interneurons are predominantly of the A type and attributable to coexpression of Kv4.2 and Kv4.1 subunits. J Neurosci 18 (1998) 3124-3137
357. + channels in therapeutics. In: Soria B., and Ceña V. (Eds). Ion Channel Pharmacology (1998), Oxford University Press, Oxford 229-245
358. Soria B., and Ceña V. Ion Channel Pharmacology (1998), Oxford University Press, Oxford
359. + channels. Biochem J 388 (2005) 455-464
360. + channel structure from a complete functional map of the molecular surface of charybdotoxin. Biochemistry 33 (1994) 443-450
361. Stansfeld C.E., March S.J., Halliwell J.V., and Brown D.A. 4-Aminopyridine and dendrotoxin induce repetitive firing in rat visceral sensory neurones by blocking a slowly inactivating outward current. Neurosci Lett 64 (1986) 299-304
362. Stansfeld C.E., Marsh S.J., Parcej D.M., Dolly J.O., and Brown D.A. Mast cell degranulating peptide and dendrotoxin selectively inhibit a fast-activating potassium current and bind to common neuronal proteins. Neuroscience 23 (1987) 893-902
363. Starace D.M., and Bezanilla F. A proton pore in a potassium channel voltage sensor reveals a focused electric field. Nature 427 (2004) 548-553
364. Starkus J.G., Varga Z., and Schönherr R. Mechanisms of the inhibition of Shaker potassium channels by protons. Pflugers Arch 447 (2003) 44-54
365. Stefoski D., Davis F.A., Faut M., and Schauf C.L. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 21 (1987) 71-77
366. Stefoski D., Davis F.A., Fitzsimmons W.E., Luskin S.S., Rush J., and Parkhurst G.W. 4-aminopyridine in patients with multiple sclerosis. Neurology 41 (1991) 1344-1348
367. Stephens G.J., Garratt J.C., Robertson B., and Owen D.G. On the mechanism of 4-aminopyridine action on the cloned mouse brain potassium channel mKv1.1. J Physiol 477 (1994) 187-196
368. + channels. Proc Biol Sci 245 (1991) 101-107
369. Stork C.M., and Hoffman R.S. Characterization of 4-aminopyridine in overdose. J Toxicol Clin Toxicol 32 (1994) 583-587
370. + current in hippocampal neurons. Nature 336 (1988) 379-381
371. Strong P.N., Clark G.S., Armugam A., De-Allie F.A., Joseph J.S., Yemul V., et al. Tamulustoxin: a novel potassium channel blocker from the venom of the Indian red scorpion Mesobuthus tamulus. Arch Biochem Biophys 385 (2001) 138-144
372. Stühmer W., Ruppersberg J.P., Schroter K.H., Sakmann B., Stocker M., Giese K.P., et al. Molecular basis of functional diversity of voltage-gated potassium channels in mammalian brain. EMBO J 8 (1989) 3235-3244
373. Swartz K.J. Towards a structural view of gating in potassium channels. Nat Rev 5 (2004) 905-916
374. Swartz K.J., and MacKinnon R. An inhibitor of the Kv2.1 potassium channel isolated from the venom of a Chilean tarantula. Neuron 15 (1995) 941-949
375. + channel through multiple binding sites. Neuron 18 (1997) 665-673
376. + channels. Neuron 18 (1997) 675-682
377. Talukder G., and Harrison N.L. On the mechanism of modulation of transient outward current in cultured rat hippocampal neurons by di- and trivalent cations. J Neurophysiol 73 (1995) 73-79
378. Targ E.F., and Kocsis J.D. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 328 (1985) 358-361
379. Tasaki I., and Takeuchi T. Der am Ranvierischen Knoten entstehende Aktionsstrom und seine Bedeutung für die Erregungstleitung. Pflugers Arch Ges Physiol 244 (1941) 696-698 (in German)
380. Tasaki I., and Takeuchi T. Weitere Studien über den Aktionsstrom der markhaltigen Nervenfaser und über die elektrosaltatorische Übertragung des Nervenimpulses. Pflugers Arch Ges Physiol 245 (1942) 764-782 (in German)
381. Tawara Y. Fugu dokuso kenkyu hokoku. (in Japanese). Yakushigaku Zasshi 29 (1909) 587-625
382. Tempel B.L., Jan Y.N., and Jan L.Y. Cloning of a probable potassium channel gene from mouse brain. Nature 332 (1988) 837-839
383. + channels. Toxicon 140 (2000) 135-185
384. Terlau H., and Olivera B.M. Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol Rev 84 (2004) 41-68
385. The International Human Genome Mapping Consortium. A physical map of the human genome. Nature 409 (2001) 934-941
386. Theakston R.D.G., and Kamiguti A.S. A list of animal toxins and some other natural products with biological activity. Toxicon 40 (2002) 579-651
387. Thesleff S. Aminopyridine and synaptic transmission. Neuroscience 5 (1980) 1413-1419
388. Thompson S.H. Three pharmacologically distinct potassium channels in molluscan neurones. J Physiol (Lond) 265 (1977) 465-488
389. Thompson S.J. Aminopyridine block of transient potassium current. Gen Physiol 80 (1982) 1-18
390. Traugott U., and Raine C.S. The neurology of myelin disorders. In: Morell P. (Ed). Myelin. 2nd ed. (1984), Plenum Press, New York 311-335
391. Tseng G.N. Different state dependencies of 4-aminopyridine binding to rKv1.4 and rKv4.2: role of the cytoplasmic halves of the fifth and sixth transmembrane segments. J Pharmacol Exp Ther 290 (1999) 569-577
392. Tseng G.-N., Jiang M., and Yao J.-A. Reverse use dependence of Kv4.2 blockade by 4-aminopyridine. J Pharmacol Exp Ther 279 (1996) 865-876
393. + channel. J Gen Physiol 82 (1993) 1057-1083
394. Tytgat J., Chandy K.G., Garcia M.L., Gutman G.A., Matin-Eauclaire M.F., van der Walt J.J., et al. A unified nomenclature for short-chain peptides isolated from scorpion venoms: alpha-KTx molecular subfamilies. TiPS 20 (1999) 4444-4447
395. + channel blockers on the clinical course and histological features of experimental allergic encephalomyelitis. Acta Neurol Scand 90 (1994) 299-301
396. University College London (UCL). The HGNC Gene Family Nomenclature. Potassium Channel Gene Family Nomenclature at http://www.gene.ucl.ac.uk/nomenclature/genefamily/KCN.shtml and the Nomenclature of the Potassium Channel Superfamily at http://www.ipmc.cnrs.fr/∼duprat/ipmc/nomenclature.htm.
397. VanDiemen H.A.M., Polman C.H., VanDongen T.M., VanLoenen A.C., Nauta J.J., Taphoorn M.J., et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, crossover study. Ann Neurol 32 (1992) 123-130
398. VanDiemen H.A.M., Polman C.H., Koetsier J.C., VanLoenen A.C., Nauta J.J., Bertelsmann F.M., et al. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related efficacy and safety. Clin Neuropharmacol 16 (1993) 195-204
399. + channel function by deletions at the N- and C-termini. Neuron 5 (1990) 433-443
400. + channels. Proc Biol Sci 248 (1992) 9-18
401. Velluti J.C., Caputi A., and Macadar O. Limbic epilepsy induced in the rat by dendrotoxin, a polypeptide isolated from the green mamba (Dendroaspis angusticeps) venom. Toxicon 25 (1987) 649-657
402. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., et al. The sequence of the human genome. Science 291 (2001) 1304-1351
403. + channels. J Biol Chem 280 (2005) 21246-21255
404. Vogel W., and Schwarz J.R. Voltage-clamp studies in axons: macroscopic and single-channel currents. In: Waxman S.G., Kocsis J.D., and Stys P.K. (Eds). The Axon: Structure, Function and Pathophysiology (1995), Oxford University Press, New York 257-280
405. Wagoner P.K., and Oxford G.S. Aminopyridines block an inactivating potassium current having slow recovery kinetics. Biophys J 58 (1990) 1481-1489
406. + channels containing Kv1.1 and 1.2 α subunits. Eur J Biochem 263 (1999) 222-229
407. + channels in terminal and juxtaparanodal regions of neurons. Nature 365 (1993) 75-79
408. Wang H., Kunkel D.D., Schwartzkroin P.A., and Tempel B.L. Localization of Kv1.1 and Kv1.2, two K channel proteins, to synaptic terminals, somata, and dendrites in the mouse brain. J Neurosci 14 (1994) 4588-4599
409. Waxman S.G. Membranes, myelin and the pathophysiology of multiple sclerosis. N Engl J Med 306 (1982) 1529-1533
410. Waxman S.G. Voltage-gated ion channels in axons: localization, function, and development. In: Waxman S.G., Kocsis J.D., and Stys P.K. (Eds). The Axon: Structure, Function and Pathophysiology (1995), Oxford University Press, New York 218-243
411. Waxman S.G. Multiple Sclerosis as a Neuronal Disease (2005), Elsevier Academic Press, Amsterdam
412. Waxman S.G., Kocsis J.D., and Stys P.K. The Axon: Structure, Function and Pathophysiology (1995), Oxford University Press, New York
413. Waxman S.G., and Ritchie J.M. Demyelinating Diseases Basic and Clinical Electrophysiology. Advances in Neurology vol. 31 (1981), Raven Press, New York
414. + current diversity is produced by an extended gene family conserved in Drosophila and mouse. Science 248 (1990) 599-603
415. + channel complementary DNA. Neuroscience 50 (1992) 935-946
416. White J.A., McAlpine P.J., Antonarakis S., Cann H., Eppig J.T., Frazer K., et al. Guidelines for human gene nomenclature 1997. HUGO Nomenclature Committee. Genomics 45 (1997) 468-471
417. + channels as therapeutic drug targets. Pharmacol Ther 94 (2002) 157-182
418. Wissmann R., Bildl W., Oliver D., Beyermann M., Kalbitzer H.-R., Bentrop D., et al. Solution structure and function of the "tandem inactivation domain" of the neuronal A-type potassium channel Kv1.4. J Biol Chem 278 (2003) 16142-16150
419. Yan L., Herrington J., Goldberg E., Dulski P.M., Bugianesi R.M., Slaughter R.S., et al. Stichodactyla helianthus peptide, a pharmacological tool for studying Kv3.2 channels. Mol Pharmacol 67 (2005) 1513-1521
420. Yang N., George Jr. A.L., and Horn R. Molecular basis of charge movement in voltage-gated sodium channels. Neuron 16 (1996) 113-122
421. Yang W.-P., Levesque P.C., Little W.A., Conder M.L., Ramakrishnan P., Neubauer M.G., et al. Functional expression of two KvLQT1-related potassium channels responsible for inherited idiopathic epilepsy. J Biol Chem 273 (1998) 19419-19423
422. Yao J.A., and Tseng G.N. Biophys J 64 (1993) A313
423. Yao J.A., and Tseng G.N. Modulation of 4-AP block of a mammalian A-type K channel clone by channel gating and membrane voltage. Biophys J 67 (1994) 130-142
424. Yeh J.Z., Oxford G.S., Wu C.H., and Narahashi T. Dynamics of aminopyridine block of potassium channels in squid axon membrane. J Gen Physiol 68 (1976) 519-535
425. + channel allows inactivation to be modulated by metal binding. Biophys J 66 (1994) 1068-1075
426. Zagotta W.N., Hoshi T., and Aldrich R.W. Restoration of inactivation in mutants of Shaker potassium channel inactivation. Science 250 (1990) 568-571
427. Zagotta W.N., Hoshi T., and Aldrich R.W. Shaker potassium channel gating: I. Transitions near the open state. J Gen Physiol 103 (1994) 321-362
428. Zagotta W.N., Hoshi T., and Aldrich R.W. Shaker potassium channel gating: II. Transitions in the activation pathway. J Gen Physiol 103 (1994) 279-319
429. Zagotta W.N., Hoshi T., and Aldrich R.W. Shaker potassium channel gating: III. Evaluation of kinetic models for activation. J Gen Physiol 103 (1994) 321-362
430. Zhang N., Li M., Chen X., Wang Y., Wu G., Hu G., et al. Solution structure of BmKK2, a new potassium channel blocker from the venom of Chinese scorpion Buthus martensi Karsch. Proteins 55 (2004) 835-845
431. Ziai M.R., Russek S., Wang H., Beer B., and Blume A.J. Mast cell degranulating peptide: a multi-functional neurotoxin. J Pharm Pharmacol 42 (1990) 457-461